Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

2.225 +0.065 (+3.01%)
Streaming Delayed Price Updated: 11:21 AM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Apr. 27, 2021: UPS, ALDX, FISV, PFPT, GOOG
Today's 5 Stock Ideas: United Postal Service (UPS) - Shares were up roughly 8% Tuesday morning. The company reported better-than-expected Q1 EPS and sales results... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Aldeyra Therapeutics (NASDAQ:ALDX) stock moved upwards by 25.29% to $13.92 during Tuesday's pre-market session. The company's market cap stands at $661.8... 
Via Benzinga
Aldeyra Therapeutics Stock Is Trading Higher On Acing Allergic Conjunctivitis Study With Reproxalap
Aldeyra Therapeutics Inc (NASDAQ: ALDX) has announced positive top-line results from the Phase 3 INVIGORATE trial evaluating 0.25% reproxalap, in... 
Via Benzinga
24 Stocks Moving in Tuesday's Pre-Market Session
Gainers RiceBran Technologies (NASDAQ: RIBT) shares rose 29.1% to $1.20 in pre-market trading. RiceBran Technologies is scheduled to host a conference call on April 28th to... 
Via Benzinga
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE Clinical Trial
From Aldeyra Therapeutics, Inc.
Via Business Wire
44 Biggest Movers From Yesterday
Gainers KnowBe4, Inc. (NASDAQ: KNBE) shares jumped 50.9% to close at $24.14 on Thursday after the company priced its IPO at $16 per share. Neuropace, Inc. (NASDAQ: NPCE) shares... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.